U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H69NO12
Molecular Weight 755.9754
Optical Activity UNSPECIFIED
Defined Stereocenters 16 / 16
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MITEMCINAL

SMILES

[H][C@@]2(O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(OC)C(=O)[C@@H](C)C3=C(C)C[C@@](C)(O3)[C@]([H])(O[C@@H]4O[C@H](C)C[C@@H]([C@H]4O)N(C)C(C)C)[C@H]2C

InChI

InChIKey=BELMMAAWNYFCGF-PZXAHSFZSA-N
InChI=1S/C40H69NO12/c1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29/h20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3/t22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-/m1/s1

HIDE SMILES / InChI

Molecular Formula C40H69NO12
Molecular Weight 755.9754
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 16 / 16
E/Z Centers 0
Optical Activity UNSPECIFIED

Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O43193
Gene ID: 2862.0
Gene Symbol: MLNR
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

12 weeks of treatment with oral tablets given twice a day of GM-611 (Mitemcinal) 5mg, 10mg
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:19:26 UTC 2023
Edited
by admin
on Sat Dec 16 17:19:26 UTC 2023
Record UNII
6X5NRJ664L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MITEMCINAL
INN   WHO-DD  
INN  
Official Name English
8,9-DIDEHYDRO-N-DEMETHYL-9-DEOXO-6,11-DIDEOXY-6,9-EPOXY-N-ISOPROPYL-12-O-METHYL-11-OXOERYTHROMYCIN
Common Name English
mitemcinal [INN]
Common Name English
Mitemcinal [WHO-DD]
Common Name English
ERYTHROMYCIN, 8,9-DIDEHYDRO-N-DEMETHYL-9-DEOXO-6,11-DIDEOXY-6,9-EPOXY-12-O-METHYL N-(1-METHYLETHYL)-11-OXO-
Common Name English
Code System Code Type Description
WIKIPEDIA
MITEMCINAL
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
EPA CompTox
DTXSID00870028
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
ChEMBL
CHEMBL2110756
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
SMS_ID
300000037001
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
PUBCHEM
6918267
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
DRUG BANK
DB06587
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
NCI_THESAURUS
C166967
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
INN
8171
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
FDA UNII
6X5NRJ664L
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
MESH
C103741
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
CAS
154738-42-8
Created by admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY